Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4.70
ALIOF's Cash to Debt is ranked higher than
66% of the 1281 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. ALIOF: 4.70 )
ALIOF' s 10-Year Cash to Debt Range
Min: 2.7   Max: No Debt
Current: 4.7

Equity to Asset 0.72
ALIOF's Equity to Asset is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALIOF: 0.72 )
ALIOF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.72
Current: 0.72

0.5
0.72
Interest Coverage 9.90
ALIOF's Interest Coverage is ranked higher than
52% of the 569 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALIOF: 9.90 )
ALIOF' s 10-Year Interest Coverage Range
Min: 0.3   Max: 9999.99
Current: 9.9

0.3
9999.99
F-Score: 6
Z-Score: 13.43
M-Score: -1.23
WACC vs ROIC
7.89%
72.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.98
ALIOF's Operating margin (%) is ranked higher than
96% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -83.68 vs. ALIOF: 30.98 )
ALIOF' s 10-Year Operating margin (%) Range
Min: 0.68   Max: 28.36
Current: 30.98

0.68
28.36
Net-margin (%) 36.59
ALIOF's Net-margin (%) is ranked higher than
96% of the 1049 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. ALIOF: 36.59 )
ALIOF' s 10-Year Net-margin (%) Range
Min: -8.15   Max: 25.49
Current: 36.59

-8.15
25.49
ROE (%) 40.79
ALIOF's ROE (%) is ranked higher than
98% of the 1160 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. ALIOF: 40.79 )
ALIOF' s 10-Year ROE (%) Range
Min: -8.85   Max: 53.58
Current: 40.79

-8.85
53.58
ROA (%) 25.85
ALIOF's ROA (%) is ranked higher than
98% of the 1286 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ALIOF: 25.85 )
ALIOF' s 10-Year ROA (%) Range
Min: -5.18   Max: 21.05
Current: 25.85

-5.18
21.05
ROC (Joel Greenblatt) (%) 118.32
ALIOF's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1251 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. ALIOF: 118.32 )
ALIOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 2.31   Max: 174.15
Current: 118.32

2.31
174.15
Revenue Growth (3Y)(%) -0.90
ALIOF's Revenue Growth (3Y)(%) is ranked higher than
76% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ALIOF: -0.90 )
ALIOF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -25.8   Max: 21.5
Current: -0.9

-25.8
21.5
EBITDA Growth (3Y)(%) 3.00
ALIOF's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -7.20 vs. ALIOF: 3.00 )
ALIOF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.4   Max: 37.9
Current: 3

-48.4
37.9
EPS Growth (3Y)(%) 6.80
ALIOF's EPS Growth (3Y)(%) is ranked higher than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. ALIOF: 6.80 )
ALIOF' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.8   Max: 47.7
Current: 6.8

-35.8
47.7
» ALIOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.70
ALIOF's P/E(ttm) is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 18.70 )
ALIOF' s 10-Year P/E(ttm) Range
Min: 13.52   Max: 66.51
Current: 18.7

13.52
66.51
Forward P/E 15.58
ALIOF's Forward P/E is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 15.58 )
N/A
PE(NRI) 19.40
ALIOF's PE(NRI) is ranked higher than
97% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 19.40 )
ALIOF' s 10-Year PE(NRI) Range
Min: 13.54   Max: 66.51
Current: 19.4

13.54
66.51
P/B 6.80
ALIOF's P/B is ranked higher than
64% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 6.50 vs. ALIOF: 6.80 )
ALIOF' s 10-Year P/B Range
Min: 2.35   Max: 7.28
Current: 6.8

2.35
7.28
P/S 6.70
ALIOF's P/S is ranked higher than
82% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 30.13 vs. ALIOF: 6.70 )
ALIOF' s 10-Year P/S Range
Min: 1.96   Max: 16.68
Current: 6.7

1.96
16.68
PFCF 113.70
ALIOF's PFCF is ranked higher than
89% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 113.70 )
ALIOF' s 10-Year PFCF Range
Min: 8.65   Max: 2760
Current: 113.7

8.65
2760
POCF 95.12
ALIOF's POCF is ranked higher than
89% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 95.12 )
ALIOF' s 10-Year POCF Range
Min: 8.43   Max: 240
Current: 95.12

8.43
240
EV-to-EBIT 20.42
ALIOF's EV-to-EBIT is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 20.42 )
ALIOF' s 10-Year EV-to-EBIT Range
Min: -53.3   Max: 261.7
Current: 20.42

-53.3
261.7
PEG 27.71
ALIOF's PEG is ranked higher than
95% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 27.71 )
ALIOF' s 10-Year PEG Range
Min: 0   Max: 4.8
Current: 27.71

0
4.8
Shiller P/E 40.00
ALIOF's Shiller P/E is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 40.00 )
ALIOF' s 10-Year Shiller P/E Range
Min: 30.5   Max: 41.7
Current: 40

30.5
41.7
Current Ratio 3.95
ALIOF's Current Ratio is ranked higher than
72% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ALIOF: 3.95 )
ALIOF' s 10-Year Current Ratio Range
Min: 1.75   Max: 3.95
Current: 3.95

1.75
3.95
Quick Ratio 3.80
ALIOF's Quick Ratio is ranked higher than
72% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: 4.30 vs. ALIOF: 3.80 )
ALIOF' s 10-Year Quick Ratio Range
Min: 1.7   Max: 3.8
Current: 3.8

1.7
3.8
Days Inventory 99.63
ALIOF's Days Inventory is ranked higher than
90% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 99.63 )
ALIOF' s 10-Year Days Inventory Range
Min: 88.91   Max: 123.11
Current: 99.63

88.91
123.11

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.20
ALIOF's Dividend Yield is ranked higher than
54% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ALIOF: 1.20 )
ALIOF' s 10-Year Dividend Yield Range
Min: 1.01   Max: 2.7
Current: 1.2

1.01
2.7
Dividend Payout 0.13
ALIOF's Dividend Payout is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 0.13 )
ALIOF' s 10-Year Dividend Payout Range
Min: 0.47   Max: 1.14
Current: 0.13

0.47
1.14
Yield on cost (5-Year) 1.20
ALIOF's Yield on cost (5-Year) is ranked higher than
51% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.31 vs. ALIOF: 1.20 )
ALIOF' s 10-Year Yield on cost (5-Year) Range
Min: 1.01   Max: 2.7
Current: 1.2

1.01
2.7
Share Buyback Rate 1.70
ALIOF's Share Buyback Rate is ranked higher than
98% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: -9.80 vs. ALIOF: 1.70 )
ALIOF' s 10-Year Share Buyback Rate Range
Min: 1.7   Max: -81.8
Current: 1.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 40.20
ALIOF's Price/Net Cash is ranked higher than
64% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 93.33 vs. ALIOF: 40.20 )
ALIOF' s 10-Year Price/Net Cash Range
Min: 11.79   Max: 75.62
Current: 40.2

11.79
75.62
Price/Net Current Asset Value 37.00
ALIOF's Price/Net Current Asset Value is ranked higher than
61% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 39.86 vs. ALIOF: 37.00 )
ALIOF' s 10-Year Price/Net Current Asset Value Range
Min: 4.58   Max: 21.66
Current: 37

4.58
21.66
Price/Tangible Book 9.70
ALIOF's Price/Tangible Book is ranked higher than
62% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. ALIOF: 9.70 )
ALIOF' s 10-Year Price/Tangible Book Range
Min: 2.98   Max: 10.28
Current: 9.7

2.98
10.28
Price/DCF (Projected) 2.60
ALIOF's Price/DCF (Projected) is ranked higher than
96% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 2.60 )
ALIOF' s 10-Year Price/DCF (Projected) Range
Min: 1.41   Max: 2.53
Current: 2.6

1.41
2.53
Price/Median PS Value 2.00
ALIOF's Price/Median PS Value is ranked higher than
73% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ALIOF: 2.00 )
ALIOF' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 4.56
Current: 2

0.58
4.56
Price/Graham Number 2.80
ALIOF's Price/Graham Number is ranked higher than
95% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ALIOF: 2.80 )
ALIOF' s 10-Year Price/Graham Number Range
Min: 1.4   Max: 2.97
Current: 2.8

1.4
2.97
Earnings Yield (Greenblatt) 5.10
ALIOF's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1264 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. ALIOF: 5.10 )
ALIOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 13.3
Current: 5.1

0.4
13.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ATLNE.Switzerland, ATLN.Switzerland, ACT.Germany, 0QMN.UK,
Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
Actelion Still On Growth Track Feb 18 2015 

More From Other Websites
Actelion receives marketing approval for Opsumit (macitentan) in pulmonary arterial hypertension in... Mar 26 2015
Actelion announces commencement of share repurchase program Mar 23 2015
Actelion's Uptravi Shows Long-term Benefit in GRIPHON - Analyst Blog Mar 16 2015
Selexipag (Uptravi) long-term outcome data in pulmonary arterial hypertension presented at American... Mar 15 2015
Actelion to host an investor event at American College of Cardiology (ACC.15) Mar 11 2015
Actelion's (ALIOF) Uptravi Accepted for Review by the FDA - Analyst Blog Mar 05 2015
Actelion's New Drug Application for selexipag (Uptravi) is accepted by the US FDA with a standard... Mar 03 2015
Selexipag (Uptravi) data in pulmonary arterial hypertension to be presented at American College of... Mar 02 2015
Actelion's (ALIOF) Earnings & Revenues Fall Y/Y in Q4 - Analyst Blog Feb 17 2015
Actelion to discuss full year 2014 financial results Feb 16 2015
Actelion delivers outstanding 2014 results Feb 16 2015
Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog Feb 11 2015
Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog Jan 16 2015
Actelion to present at the 33rd J.P. Morgan Healthcare Conference - Transforming our PAH portfolio Jan 12 2015
Actelion submits US FDA New Drug Application for selexipag (Uptravi) in patients with pulmonary... Dec 22 2014
Actelion submits selexipag (Uptravi) for EMA Marketing Authorisation in patients with pulmonary... Dec 22 2014
Actelion Submits Marketing Application for Uptravi in EU Dec 03 2014
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance Oct 22 2014
Ligand Up on Multi-Program Captisol Deal with Avion Pharma Aug 18 2014
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data Aug 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK